The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-line treatment for gastrointestinal stromal tumours (GISTs) harbouring sensitizing mutations in KIT or PDGFRA. Nilotonib might prove to be beneficial in other subset of patients; however, there remains an urgent unmet need to address the GIST subtypes that are therapeutic orphans.
Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes / Pantaleo, Maria A; Biasco, Guido. - In: NATURE REVIEWS. CLINICAL ONCOLOGY. - ISSN 1759-4774. - STAMPA. - 12:8(2015), pp. 440-442. [10.1038/nrclinonc.2015.107]
Gastrointestinal cancer: Management of GIST--go beyond imatinib: treat resistant subtypes
PANTALEO, MARIA ABBONDANZA;BIASCO, GUIDO
2015
Abstract
The results of the ENESTg1 trial confirm the efficacy of imatinib, but not nilotinib, as a first-line treatment for gastrointestinal stromal tumours (GISTs) harbouring sensitizing mutations in KIT or PDGFRA. Nilotonib might prove to be beneficial in other subset of patients; however, there remains an urgent unmet need to address the GIST subtypes that are therapeutic orphans.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
